Tolerance and Pharmacokinetics of TQB2450
- Registration Number
- NCT03460457
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Brief Summary
To study the pharmacokinetic characteristics of TQB2450 in the human body, recommend a reasonable regimen for subsequent research.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
- Patients with advanced malignancy diagnosed with pathology or cytology who have failed standard treatment or no standard treatment;
- 18-70 years old;Eastern Cooperative Oncology Group performance status:0-1,Life expectancy of more than 3 months;
- Main organs function is normal;
- Women of childbearing potential should agree to use and utilize an adequate method of contraception (such as intrauterine device，contraceptive and condom) throughout treatment and for at least 6 months after study is stopped；the result of serum or urine pregnancy test should be negative within 7 days prior to study enrollment，and the patients required to be non-lactating；Man participants should agree to use and utilize an adequate method of contraception throughout treatment and for at least 6 months after study is stopped;
- Patients should be voluntary and sign the informed consents before taking part in the study;
Read More
Exclusion Criteria
- Patients who have received programmed cell death protein 1(PD-1) or programmed cell death protein ligand(PD-L1) antibody treatment;
- Patients who had any> 3 degree immune-related adverse event during any previous immunotherapy received;
- Appeared severe hypersensitivity after taking other monoclonal antibody drugs;
- Other malignancies have been diagnosed in the past 2 years except cured or locally curable cancers, such as cutaneous or squamous cell carcinoma, superficial bladder cancer, cervical cancer or orthotopic carcinoma of the breast;
- Known spinal cord compression, cancer meningitis patients, new onset of central nervous system metastasis or stable control of symptoms in patients with brain metastases less than 4 weeks; asymptomatic and stable imaging without the need for corticosteroid treatment；
- Patients with hypothyroidism over 2 degrees;
- Patients with active, or who have had, and are likely to relapse, autoimmune diseases; the following patients are enrolled: skin disorders without systemic treatment (eg vitiligo, psoriasis, hair loss);
- Patients treated with glucocorticoids or other immunosuppressive agents within 4 weeks prior to dosing;
- Interstitial lung disease or non-contagious pneumonia (including past history and current illness); uncontrolled systemic diseases including diabetes, hypertension, pulmonary fibrosis, acute lung disease, etc. except for radiotherapy-induced interstitial pneumonitis;
- Serious chronic or active infections require systemic antibacterial, antifungal or antiviral treatment (allowing antiviral treatment in patients with hepatocellular carcinoma), including tuberculosis infection;
- Unstable pleural effusion, pericardial effusion or ascites;
- Significant cardiovascular diseases such as heart failure of New York Heart Academy(NYHA) Class 2 and above, myocardial infarction within the past 3 months, unstable arrhythmias (including QT interval ≥480 ms) or unstable Angina;
- Patients with immunodeficiency, including HIV positive or other acquired, congenital immunodeficiency disease, or organ transplant history;
- Hypertension (systolic BP ≥140 mmHg, diastolic BP ≥90 mmHg) still uncontrollable by one medication;
- Hepatitis B virus patients with active replication (DNA> 500 cps / mL), hepatitis C;
- The first medication interval from the patient: the last chemotherapy for at least 4 weeks, biological products at least five half-lives;
- The first medication interval from the patient: the last chemotherapy for at least 4 weeks, biological products at least five half-lives;
- Inoculated with vaccine or attenuated vaccine within 4 weeks before first administration;
- Major surgery, or unhealed wounds, ulcers or fractures within 4 weeks prior to the first dose;
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description TQB2450 TQB2450 -
- Primary Outcome Measures
Name Time Method maximum tolerated dose(MTD) 21 days dose-limiting toxicity(DLT) 21 days
- Secondary Outcome Measures
Name Time Method Peak Plasma Concentration(Cmax) 21 days Peak time（Tmax） 21 days Half life（t1/2） 21 days Area under the plasma concentration versus time curve (AUC) 21 days Clearance（CL） 21 days objective response rate(ORR) evaluated in the end of each 3 cycles up to intolerance the toxicity or progression disease (up to 24 months)